NovaDel Pharma at Rodman & Renshaw TechVest Global Conference May 12

NovaDel Pharma at Rodman & Renshaw TechVest Global Conference May
12 


FLEMINGTON, N.J., MAY 3  /PRNewswire-FirstCall/ -- NovaDel Pharma, Inc. 
(BULLETIN BOARD: NVDL) , a leading formulator of lingual spray drugs for
systemic delivery through the oral mucosa, said its chief executive officer,
Gary A. Shangold, MD, will present at the Rodman & Renshaw TechVest Global
Healthcare Conference (May 12-14) at Claridge's Hotel, London, UK.

Dr. Shangold will be presenting in the French Salon on Wednesday, May 12 at
9:25am BST, British Summer Time (4:25am EDT).

A webcast of the presentation will be available on the date of the presentation
and will be archived for 90 days.  For details go to
http://www.rodmanandrenshaw.com/.

NovaDel Pharma Inc. is a specialty pharmaceutical company engaged in the
development of novel drug delivery systems for prescription and over-the-
counter drugs. The Company's proprietary lingual spray technology delivery
system offers the patient (i) fast onset of action; (ii) improved drug safety
by reducing the required drug dosage and reducing side effects; (iii) improved
patient convenience and compliance; and (iv) enhanced dosage reliability. The
Company plans to develop such products independently and through collaborative
arrangements with major pharmaceutical and biotech companies.

Except for historical information contained herein, this document contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements involve known and unknown risks
and uncertainties that may cause the Company's actual results or outcomes to be
materially different from those anticipated and discussed herein including, but
not limited to, the ability to develop products (independently and through
collaborative arrangements), and the ability to commercialize and obtain
approval for products under development. Further, the Company operates in
industries where securities may be volatile and may be influenced by regulatory
and other factors beyond the Company's control. Important factors that the
Company believes might cause such differences are discussed in the risk factors
detailed in the Company's most recent Annual Report and Registration
Statements, filed with the Securities and Exchange Commission. In assessing
forward-looking statements contained herein, if any, the reader is urged to
carefully read all cautionary statements contained in such filings.

   Contact:
           Barry C. Cohen                  Thomas Redington
           VP New Business                 203-222-7399
            & New Product                  212-926-1733
              Development                  
           908.782.3431 ext. 31
           NovaDel Pharma Inc.


DATASOURCE: NovaDel Pharma, Inc.



CONTACT: Barry C. Cohen, VP New Business & New Product Development of

NovaDel Pharma Inc. [phone] ext. 31; or Thomas Redington,

[phone], [phone], or , for NovaDel

Pharma, Inc.



Web site:  http://www.rodmanandrenshaw.com/ 

Copyright